文献速递神经肿瘤

新诊断切除后非典型脑膜瘤的长期结局及辅助放疗的作用

Long-Term Outcomes of Newly Diagnosed Resected Atypical Meningiomas and the Role of Adjuvant Radiotherapy.
PubMed 文献 · World Neurosurg · 2018-11-14

回顾性分析2000至2012年149例新诊断并切除的非典型脑膜瘤患者,中位随访74.2个月。全切除98例、次全切除51例,53例(35%)接受辅助放疗。次全切除组辅助放疗显著改善局部控制和无进展生存,全切除组仅呈改善趋势;年龄、肿瘤大小和次全切除是更差无进展生存的显著危险因素。

要点

  • 次全切除的非典型脑膜瘤患者应接受辅助放疗,局部控制和无进展生存均有改善。
  • 全切除患者可考虑辅助放疗,但积极监测也是合理的管理方式。
  • 46例(31%)出现进展或复发,中位进展时间32.4个月,其中5例转化为世界卫生组织III级恶性脑膜瘤。

核心结论

  • 新诊断非典型脑膜瘤次全切除患者应接受辅助放疗,基于局部控制和无进展生存的改善。
  • 全切除患者可考虑辅助放疗,但积极监测是合理的管理方式,需认识到进展或复发病例可能表现侵袭性。
  • 评估辅助放疗作用的前瞻性随机试验正在进行中。

研究设计与样本

  • 回顾性分析2000至2012年149例新诊断并切除的非典型脑膜瘤患者。
  • 全切除定义为Simpson I-III级(98例),次全切除定义为IV和V级(51例)。
  • 采用Kaplan-Meier法分析局部控制、无进展生存和总生存,log-rank检验比较,多因素Cox回归分析进展或复发的危险因素。

主要发现

  • 中位随访74.2个月,53例(35%)接受辅助放疗。
  • 46例(31%)出现进展或复发,中位进展时间32.4个月。
  • 全切除亚组中辅助放疗与无进展生存改善呈趋势(P=0.0669)。
  • 次全切除亚组中辅助放疗显著改善局部控制(P=0.0183)和无进展生存(P=0.0034)。
  • 年龄、肿瘤大小和次全切除是更差无进展生存的显著危险因素,接受辅助放疗在多因素分析中与无进展生存改善相关。

关键数值与推荐

  • 46例进展或复发患者中39例接受挽救治疗,仅22例获得长期控制。
  • 5例患者转化为世界卫生组织III级恶性脑膜瘤。

临床怎么用

  • 作者结论认为次全切除的新诊断非典型脑膜瘤患者应接受辅助放疗。
  • 作者结论认为全切除患者可考虑辅助放疗,但积极监测也是合理的管理方式。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The role of adjuvant radiotherapy (ART) in patients with World Health Organization Grade II atypical meningiomas (AMs) remains controversial. METHODS: We retrospectively reviewed 149 patients with newly diagnosed resected AMs from 2000 to 2012. Gross total resection (GTR) was defined as Simpson Grades I-III and subtotal resection (STR) as Grades IV and V. Kaplan-Meier analyses of local control (LC), progression-free survival (PFS), and overall survival were performed with the log-rank test, and risk factors for progression/recurrence (P/R) were analyzed with multivariate Cox regression. RESULTS: Median follow-up was 74.2 months. GTR was achieved in 98 patients and STR in 51 patients. Fifty-three (35%) patients received ART. Overall, 46 patients (31%) experienced P/R with a median time to P/R of 32.4 months. ART was associated with a trend toward improved PFS (P = 0.0669) in the GTR subset but significantly improved LC (P = 0.0183) and PFS (P = 0.0034) in the STR subset. Age, tumor size, and STR were significant risk factors for worse PFS, whereas receiving ART was associated with improved PFS on multivariate analyses. Thirty-nine of the 46 progressive/recurrent patients underwent salvage therapy with only 22 patients experiencing long-term control. Five patients experienced transformation to World Health Organization Grade III malignant meningioma. CONCLUSIONS: Patients who undergo STR for newly diagnosed AM should receive ART based on improvements in LC and PFS. GTR patients should be considered for ART, but active surveillance is a reasonable management approach with the recognition that progressive/recurrent disease can act aggressively. Prospective, randomized trials are currently underway to evaluate the role of ART.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Zhi M, Girvigian MR, Miller MJ, et al. Long-Term Outcomes of Newly Diagnosed Resected Atypical Meningiomas and the Role of Adjuvant Radiotherapy. World Neurosurg. 2018. PMID: 30447464. doi:10.1016/j.wneu.2018.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。